Abstract
Short-chain fatty acids (SCFAs), particularly butyrate, are central microbial metabolites with local epithelial actions and increasingly recognized neuroactive signaling roles along the microbiota–gut–brain axis[1–4]. Yet, oral delivery of free butyrate salts (e.g., sodium butyrate) is constrained by two convergent barriers: (i) premature dissolution and absorption in the upper gastrointestinal tract—including stomach-level passive absorption—reducing the fraction available for distal intestinal and colonic sensing circuits[5–7], and (ii) organoleptic failure (rancid butter-like odor/taste) that undermines adherence in chronic regimens[5–7]. This report synthesizes evidence that pH-responsive enteric polymer coatings and microencapsulation approaches can function as enabling technologies to protect butyrate payloads against early release under acidic gastric conditions, delay proximal absorption, and improve acceptability by physically isolating volatile odorants[7–9]. We further connect colon- or distal gut-targeted SCFA exposure to mechanistic pathways for vagal nerve stimulation (VNS), including SCFA receptor–dependent afferent firing and downstream brainstem activation, as well as indirect endocrine transduction via L-cell GLP-1/PYY and enterochromaffin serotonin signaling[3, 10–12]. Collectively, the cited literature supports a translational thesis: for neurogastroenterology and gut–brain therapeutics, formulation—not molecule selection alone—determines whether butyrate can engage distal gut receptors and vagal afferents while remaining tolerable for real-world use[7, 9].
Introduction
SCFAs—acetate, propionate, and butyrate—are produced by bacterial fermentation of non-digestible carbohydrates/dietary fiber in the lower gut and are among the most abundant microbial metabolites in the colon[1, 13]. Multiple reviews describe SCFAs as a major communication link between gut and brain (the gut–brain axis), acting through neural, endocrine, immune, and metabolic routes[14–16]. In humans, acetate, propionate, and butyrate are frequently described as the predominant colonic SCFAs and are reported to occur in an approximate molar ratio of 60:20:20[13, 16].
Butyrate occupies a distinctive position within this triad because it is repeatedly described as a preferred fuel for colonocytes and an important determinant of epithelial integrity and inflammation control[2, 17, 18]. Mechanistically, SCFAs are ligands for GPCRs including FFAR2 (GPR43) and FFAR3 (GPR41), as well as related receptors such as GPR109a/HCAR2, which are distributed across intestinal, immune, and neural tissues[13, 19, 20]. SCFAs additionally exert intracellular effects through inhibition of histone deacetylases (HDACs), with butyrate often described as a particularly potent HDAC inhibitor among SCFAs[15, 21].
The formulation problem emerges because the relevant biological targets (colonic epithelium, enteroendocrine L-cells enriched distally, and vagal afferent terminals conveying visceral signals) are largely distal, while free butyrate salts may dissolve early and appear rapidly in peripheral blood after ingestion[5, 11]. Accordingly, the same molecule can produce divergent physiology depending on whether it is delivered as a proximal, systemically absorbed pulse versus a delayed, distal luminal signal that engages mucosal and neural sensing elements[5, 22, 23]. This report therefore focuses on enteric coating and microencapsulation technologies aimed at shifting the site and kinetics of butyrate release, while simultaneously addressing its odor and taste liabilities[7, 24, 25].
Pharmacology and pharmacokinetics
Butyrate is a four-carbon SCFA produced in the colon and repeatedly framed as critical for gut health and broader systemic functions, including metabolism and immune modulation[2, 26]. Multiple sources emphasize that butyrate is largely taken up by colonic epithelial cells and used as an energy substrate, supporting mitochondrial oxidative metabolism and ATP production in colonocytes[18, 26]. Classic ex vivo evidence summarized in a colonocyte metabolism review indicates that in colonocyte suspensions provided 10 mM butyrate, >70% of oxygen consumption was attributed to butyrate oxidation[17], consistent with butyrate’s described role as a dominant oxidative fuel in the colonic epithelium[2, 17]. A further synthesis notes that 80–95% of SCFAs produced by bacteria are absorbed by the colon, leaving minimal concentrations in feces[17].
Molecular properties and absorption machinery
A central physicochemical feature of butyrate is its weak-acid character, with a reported and predominant dissociation at physiological colonic pH (5.0–6.5)[20]. Cellular uptake is described as occurring via both passive nonionic diffusion and carrier-mediated pathways[26]. Specific transporters cited for butyrate and other SCFAs include proton-coupled monocarboxylate transporters (e.g., MCT1/SLC16A1) and sodium-coupled monocarboxylate transporters (e.g., SMCT1/SLC5A8)[20, 27]. Additional transporter families (MCT4/MCT5; Slc16a3/Slc16a4) and an apical efflux pump (ABCG2) are also implicated in intestinal epithelial handling of butyrate and other monocarboxylates[27].
First-pass utilization and systemic appearance
A recurring pharmacokinetic theme is rapid utilization of butyrate within the gut–liver axis. One human-focused butyrate formulation comparison states that absorbed butyrate is metabolized in intestinal epithelial cells (conversion to acetyl-CoA with entry into the Krebs cycle for ATP production), with only ~2% entering portal circulation to the liver, where it is further metabolized[26]. A pig study similarly notes that butyrate can be absorbed from the gut and entirely metabolized in gut mucosa or liver, making systemic detection difficult[2]. Together, these descriptions imply that systemic measurements may underrepresent luminal exposure and epithelial metabolism, particularly when release is targeted distally rather than proximally[2, 26].
Receptor and epigenetic pharmacology
Butyrate signaling is not limited to energy metabolism. Several sources describe butyrate as a ligand for GPCRs and as an HDAC inhibitor that modulates gene expression and inflammation[2, 21]. Butyrate is also described as capable of epigenetically upregulating the μ-opioid receptor in a human overweight/obesity trial paper discussing mechanistic hypotheses[21]. A mechanistic colon cancer study further details that SCFAs—including butyrate—activate FFAR2, which couples to Gi to inhibit cAMP signaling and to Gq to promote calcium mobilization, with downstream reductions in cAMP–PKA–CREB signaling and effects on HDAC expression; it also states that SCFAs suppress class I and class IIa HDACs[19]. These mechanistic constructs support the plausibility that butyrate can act as both a metabolite and a signaling molecule, with downstream consequences relevant to neural and immune pathways implicated in gut–brain modulation[3, 12].
Formulation-dependent pharmacokinetic behavior
Because free butyrate salts may be absorbed early, several lines of evidence emphasize the importance of prodrug or protected delivery. A butyrate product comparison trial in humans reports that plasma appearance of tributyrin (a butyrate triglyceride prodrug) was significantly lower than sodium butyrate and lysine butyrate, likely due to enzymatic cleavage requirements that delay or reduce release from tributyrin[26]. In parallel, a human overweight/obesity crossover study using butyrate and hexanoate-enriched triglycerides provides in vitro digestion evidence that esterifying SCFAs into certain triglyceride formats can markedly reduce gastric release (e.g., ~14% release in the gastric compartment with ~86% remaining esterified for one formulation)[21], though alternative triglyceride mixtures may undergo substantial gastric cleavage, releasing most acids as free form from the stomach[21]. These contrasting results highlight that not all “prodrug” or esterified strategies are equivalent in delaying proximal release, and that formulation chemistry and enzymology govern where bioactive butyrate is liberated[21].
Gastric degradation and premature absorption
A central obstacle for colonic targeting is that unprotected SCFAs can appear rapidly in peripheral blood after oral ingestion. A human supplementation study on serum SCFA profiles states that the rapid increase in circulating SCFA concentrations is likely explained by passive absorption from the stomach[5]. The same source reasons that capsule contents likely entered stomach fluid within ~30 minutes after supplementation based on expected gastric transit time and capsule formulation[5]. It also states that because SCFAs have , the majority of ingested SCFA molecules would be in associated (nonionic), lipid-soluble forms able to cross the stomach epithelium[5]. This combination of rapid disintegration/exposure and favorable nonionic diffusion provides a mechanistic basis for why immediate-release SCFA dosing may fail to deliver a meaningful luminal signal to distal intestine or colon[5].
Consistent with this concept, a clinical review of sodium butyrate and microencapsulated forms emphasizes that oral administration of some butyric acid salt formulations does not deliver an appropriate amount to the colon because butyrate anion is rapidly absorbed in the stomach and initial parts of the small intestine after release[7]. Another review similarly states that butyric acid taken orally is very rapidly absorbed and metabolized in the initial gastrointestinal tract and that the supplement form should be chosen to ensure delivery to downstream sections of the intestine[6]. In an animal production model, investigators note that orally given butyrate is quickly absorbed and metabolized throughout the gastrointestinal tract, limiting delivery to the hindgut[28].
The implications for vagal-targeted SCFA delivery are twofold. First, premature absorption alters the anatomical site of receptor engagement: rather than activating colonic mucosal receptors and enteric/vagal circuits originating distally, exposure may concentrate in the stomach or proximal small intestine[5, 7]. Second, early absorption can blunt endocrine responses expected from distal L-cell stimulation; the pig brain metabolism study explicitly suggests that butyrate may never have reached L-cells and instead was absorbed at the stomach level, potentially explaining a lack of plasma GLP-1 increase[2]. These observations support the formulation thesis that protecting butyrate from early release is necessary to test—and potentially harness—distal gut–brain signaling mechanisms[2, 7].
Organoleptic failure
The sensory profile of butyrate is consistently described as a practical barrier to chronic oral use. A review on obesity/IBD/pregnancy/colorectal cancer states that butyric acid is an oily liquid with an unpleasant odor of rancid butter, whereas sodium butyrate has a milder odor and greater stability but remains organoleptically challenging[6]. A clinical review focused on sodium butyrate emphasizes that the unpleasant taste and rancid-butter odor dictate the necessity of protected forms to improve tolerance and patient compliance[7]. In a human SCFA supplementation study, participants reported a mildly unpleasant taste and smell relating specifically to butyrate supplements, and the large capsule size used was mildly-to-moderately uncomfortable to swallow for most participants[5]. A pharmacokinetic comparison study similarly notes practical concerns that some butyrate supplements provide unpleasant odor and flavor, presenting adherence challenges for oral ingestion[26].
Odor and taste masking is therefore not a cosmetic consideration but an enabling requirement for adequate exposure in chronic protocols. The polymeric micelle prodrug study underscores the persistence of this issue by stating that butyrate, even with enteric coating or encapsulation, possesses a foul and lasting odour and taste[25], while simultaneously reporting that their polymer formulations mask smell and taste while functioning as carriers that release butyrate over time through GI transit[25]. Microencapsulation strategies for tributyrin (a butyrate source) similarly cite the need to mitigate unpleasant sensory qualities and negative odor attributes as major drivers for encapsulation research and processing optimization[29, 30]. Collectively, these sources indicate that patient acceptability and manufacturability considerations are structurally linked to pharmacokinetics: formulations that reduce volatilization and sensory perception can also reduce premature release and shift delivery distally[7, 24].
Enteric coating technology
Enteric and colon-targeted coatings attempt to exploit pH differences along the gastrointestinal tract. A state-of-the-art review of enteric coatings for colonic drug delivery notes that polymethacrylates with pH-dependent dissolution thresholds in the range of pH 6.0 to 7.0 are mainly used as coating agents to protect drug cores from gastric and small intestinal contents, citing Eudragit® S, Eudragit® L, and Eudragit® FS as common brands[9]. Another review of colon-targeted oral drug delivery systems explains that incorporating drugs in pH-sensitive polymers can protect actives from acidic stomach and proximal small intestine conditions, with polymers breaking down in more basic pH of the terminal ileum to provide targeted drug delivery to the colon[31]. It also states that methacrylic-acid based polymers (Eudragit®) and polymethacrylate coatings such as Eudragit® L and Eudragit® S are frequently used and can be mixed in different ratios to optimize dissolution[31].
Polymer examples and dissolution thresholds
Evidence in the provided corpus supports the following polymer-specific claims. First, Eudragit S100 is described as an anionic copolymer of methacrylic acid and methyl methacrylate with free carboxyl to ester group ratio approximately 1:2 and a dissolution threshold pH slightly above 7.2[8]. In a colon-targeted mesalamine microsphere study, the microspheres were coated with Eudragit S100 to prevent drug release in the stomach[8], and the formulation showed no release in simulated gastric fluid, negligible release in simulated intestinal fluid, and maximum release in the colonic environment[8]. Second, for liposomal colonic delivery, an ES100 (Eudragit S100) coating is described as having a solubility threshold of pH 7, rendering it insoluble at lower pH values in the stomach and upper small intestine while allowing release at the small intestine–colon junction where pH 7 occurs[32]. Third, a broader pH-responsive polymer review states that polymer coatings are unaffected by gastric acid but ionize and degrade above a certain pH threshold, and that polymer solubility is low in acidic environments but increases as pH rises[33].
GI pH variability and colon-targeting limits
A major practical limitation is inter-individual and regional GI pH variability. The enteric coating state-of-the-art review reports that acidic pH values were disclosed in the right colon of healthy subjects in a radiotelemetry study[9], and attributes the pH fall to accumulation of short-chain fatty acids in the cecum and proximal large intestine from bacterial fermentation activity[9]. This is directly relevant to SCFA delivery, because the payload (butyrate and other SCFAs) can itself contribute to local pH shifts that may alter enteric polymer dissolution dynamics and, potentially, release location[9]. The same review notes that the reliability of pH-dependent formulations has been recurrently questioned over the last decades[9].
A time-based colon delivery review similarly states that pH-dependent formulations relying on gradual pH increase from stomach to colon faced inconsistency because pH can rise above 7 in the ileum followed by a sharp drop to about 6.4 in the cecum, with a slow aboral rise afterward[34]. These data motivate hybrid approaches that combine pH triggers with time-dependent or multi-layer coatings, especially when targeting specific colonic regions under variable physiological conditions[9, 34].
Combination coatings to broaden the release window
Several sources directly support combining methacrylic acid copolymers to tune dissolution across a pH window. A study coating mesalazine tablets with varying combinations of Eudragit L100 and Eudragit S100 demonstrates that drug release can be manipulated by changing L100:S100 ratios within pH 6.0–7.0, and that combined coatings can overcome the issue of high gastrointestinal pH variability among individuals; it further states that the combination system is superior to using either polymer alone for colon targeting[35]. A related pellet formulation study describes combining pH-dependent polymers (Eudragit S100 and L100) with a time-dependent polymer (Eudragit RS) to control colonic release across dissolution media (pH 1.2, 6.5, 6.8, 7.2), reporting that drug release in the colon could be controlled by addition of Eudragit RS to pH-dependent polymers[36]. These studies provide a formulation logic for SCFA payloads: a broader dissolution profile and time-lag can reduce premature ileal release while still permitting colonic delivery under variable pH conditions[35, 36].
Microencapsulation approaches
Microencapsulation is presented across multiple sources as a practical strategy to (i) protect butyrate from early release/absorption and (ii) mask its odor and taste. A Spanish review on butyrate in intestinal disease states that microencapsulation allows not only overcoming poor organoleptic characteristics of tributyrin but also formulating it as a granulate enabling oral once-daily administration and positive therapeutic adherence[24]. A clinical review of sodium butyrate similarly argues that microencapsulation can facilitate controlled release of sodium butyrate in different digestive tract sections with predominant release in distal small and large intestine, explicitly positioning this approach as a solution to rapid absorption and palatability limitations[7]. Another review describes an “effective method” using microencapsulation that encapsulates sodium butyrate molecules in lipid microbeads placed in a gel capsule, and notes that these preparations are best taken after a meal when pancreatic lipase secretion increases and gradually releases butyric acid from microbeads[6].
Multiparticulates, beads, and protected cores
Even outside human contexts, controlled-release beads provide direct evidence that protected systems can resist gastric conditions. An in vitro/in vivo study of calcium [1-(14)C]butyrate reports that protected beads released only 3.4 ± 0.2% of radiocarbon into gastric fluid after 2 hours of incubation, and that following a gastric-to-intestinal simulation sequence total release was 17.4 ± 0.8%[37]. In vivo, respiratory (14)CO2 release peaked at 1.5 hours for unprotected butyrate but at 4 hours for protected beads, indicating delayed absorption/oxidation consistent with prolonged intestinal delivery[38]. Although this model uses broiler chicks, it provides mechanistic support that coating/protection can shift the timing of butyrate availability downstream[38].
Lipid matrices and polymer-coated microcapsules
Lipid matrices are commonly invoked as protective barriers. A diet-induced obese rat study notes that microencapsulation in lipid matrices was developed to protect SCFAs from proximal intestinal digestion and target release to the large intestine[22], explicitly contrasting microencapsulated products expected to slowly release SCFAs in the lower GI tract with non-encapsulated sodium butyrate[22]. In a chicken infection model, microencapsulated sodium butyrate is described as coated with a “polymer enteral material,” containing 40% sodium butyrate, with the rationale that delaying enteric release reduces small intestinal absorption and enhances colonic delivery; the study also reports superior effectiveness versus non-encapsulated sodium butyrate at the same supplemental amount[28].
Polymeric prodrug micelles as an alternative to classical enteric coatings
A distinct, mechanistically explicit approach is the use of butyrate-prodrug polymeric micelles. In this strategy, butyrate is linked to a micelle-forming polymer chain via ester bonds, enabling hydrolysis by digestive esterases and controlled release in the GI tract[25]. The authors validated release in simulated gastric and intestinal fluids and report negligible butyrate release in simulated gastric fluid for hours, with sustained slow release over weeks, while in simulated intestinal fluid with high pancreatin esterase concentration the micelles released most of their butyrate within minutes[25]. They further state that the butyrate-conjugated polymer formulations release butyrate in distinct segments of the lower GI tract, in contrast to sodium butyrate, which is predominantly absorbed in the stomach[25]. Beyond pharmacokinetics, they explicitly state that polymer formulations mask butyrate’s smell and taste and act as carriers to release butyrate over time as micelles transit the GI tract[25].
Capsule shell approaches and delayed release systems
Delayed-release can also be imparted at the capsule-shell or capsule-in-capsule level. An in vitro evaluation of targeted-release capsules (developed for pancreatin protection) states that DRcaps® are composed of combined HPMC and gellan gum and support delayed release in the small intestine[39]. The same study states that adding gellan gum in DR capsules protects HPMC from breaking down in the low-pH stomach environment, allowing intact capsules to transit to the intestines[39]. Although this work focuses on pancreatin and uses butyrate generation from tributyrin as an activity readout, it provides generalizable evidence that capsule-shell material selection can be used to prevent early disintegration in acidic stomach conditions and thereby preserve payload integrity until later phases[39].
Comparison table
The table below synthesizes protected-delivery strategies described in the supplied sources, emphasizing the targeted region, gastric resistance evidence, and acceptability implications.
| Strategy | Mechanism of protection and trigger | Evidence for reduced gastric release or delayed appearance | Acceptability benefit | Representative sources |
|---|---|---|---|---|
| pH-responsive polymethacrylate enteric coating (Eudragit) | Insoluble at low pH; dissolves above polymer threshold (often ~pH 6–7 range; S100 slightly above 7.2) enabling ileum/colon release[8, 9] | Eudragit S100–coated chitosan microspheres showed no release in simulated gastric fluid and maximal release in colonic environment[8] | Indirect via containment of payload/odors by barrier layer (not always explicitly tested) | Mesalamine microspheres coated with S100[8]; general coating reviews[9] |
| Combination pH + time-dependent coatings | Mix pH-dependent polymers (L100/S100) and time-dependent polymer (RS) to tune lag time and broaden pH robustness[35, 36] | Dissolution across pH progression media demonstrates tunable lag/release; combination systems address pH variability[35, 36] | Indirect via delayed release and reduced premature exposure | L100/S100 ratio manipulation[35]; RS addition controls colonic release[36] |
| Lipid-matrix microencapsulation | Lipid matrix protects SCFAs from proximal digestion and targets lower-GI release[22] | Microencapsulation positioned to reduce proximal absorption and enhance colonic delivery[28] | Can reduce odor/taste and improve handling depending on design[7, 24] | Microencapsulated SB review[7]; chicken MS-SB study[28] |
| Protected beads (multiparticulate) | Encapsulation/protected bead structure slows dissolution | Protected calcium [1-(14)C]butyrate beads released 3.4% into gastric fluid after 2 h[37]; delayed in vivo (14)CO2 peak at 4 h vs 1.5 h unprotected[38] | Not directly assessed | Protected beads study[37, 38] |
| Polymeric butyrate-prodrug micelles | Covalent ester linkage; minimal release in gastric fluid; rapid esterase-triggered intestinal release; designed for lower-GI delivery[25] | Negligible release in simulated gastric fluid; rapid release in simulated intestinal fluid with pancreatin[25] | Explicit masking of smell/taste by polymer formulation[25] | Butyrate-prodrug micelles[25] |
Vagal nerve stimulation mechanisms
A mechanistic foundation for “SCFA-driven vagal stimulation” is supported by convergent evidence that SCFAs can activate afferent neural pathways and induce downstream central activation. A broad perspective review explicitly states that, in addition to effects on gut hormone release, SCFAs directly activate the vagus nerve[3], and provides an example that butyrate increases the firing rate of vagal afferent neurons transmitting signals from gut to brain[3]. It further states that FFAR3 is expressed on vagal afferents coming from the gut and that vagal-FFAR3 knockout alters feeding behavior and blunts appetite suppression by propionate[3]. These findings align with other reviews describing SCFAs as neuroactive metabolites involved in microbiota–gut–brain communication via neural (vagal), endocrine (GLP-1/PYY), and immune pathways[16, 40].
Direct receptor-linked afferent activation
High-resolution evidence that colonic SCFA receptors can drive gut–brain signaling is provided by chemogenetic/physiological studies. One such study reports that perfusion of colonic tissue with propionate (C3) resulted in a marked increase in nerve firing rate in an ex vivo preparation[10]. The same work states that sensory signaling from the proximal colon is communicated to the nodose ganglia via the vagal nerve[10], and reports that an FFA3-selective activator (TUG-1907) increased nerve activity in wild-type tissue but not in FFA3 knockout tissue, confirming the role of FFA3 in increasing peripheral nerve activity from the proximal colon in response to SCFAs[10]. In vivo, rectal/colonic C3 exposure increased c-Fos-positive neurons compared with saline, indicating downstream activation of central pathways (spinal cord activity markers) triggered by colonic SCFA receptor activation[10]. The authors summarize this as establishing and validating an SCFA–gut–brain axis in which activation of colonic FFA2/FFA3 results in changes in spinal cord activity[10].
Complementary findings are reported in a related analysis emphasizing that short-chain fatty acid receptors activated by agonists introduced into the colon can activate afferent nerve bundles in the enteric nervous system and promote neuronal activation at the level of the dorsal horn of the spinal cord[41]. Such receptor-defined pathways strengthen the translational logic of colonic delivery: if the therapeutic goal is vagal/central modulation, ensuring that agonists are present in the correct anatomical lumen for receptor activation becomes a formulation-critical constraint[10, 41].
Indirect endocrine signaling via L-cells
A second mechanistic route is endocrine transduction via enteroendocrine L-cells, which are described as being predominantly enriched in the distal gastrointestinal tract and releasing GLP-1 and PYY in response to nutrient and bacterial stimuli including SCFAs[11]. A study on FFAR2 circuitry in L-cells states that activation of FFAR2 on enteroendocrine L-cells mediates secretion of GLP-1 and PYY, hormones described as key regulators of central appetite control[11]. The same paper reports that butyrate promotes enteroendocrine differentiation toward a PYY-biased phenotype via a spatially regulated FFAR2–Gi axis[42], supporting a mechanism by which chronic or repeated distal exposure to butyrate could shape endocrine signaling capacity at the mucosal interface[42].
Mechanistic evidence for SCFA-induced GLP-1/PYY output is also available from isolated colon models. In an isolated perfused rat colon, luminal infusion of 100 mM butyrate significantly increased GLP-1 and PYY secretion[43]. A related dataset suggests acetate and butyrate (but not propionate) increase colonic GLP-1 secretion and, to a lesser extent, PYY secretion after enhancement of intracellular cAMP, with the authors proposing uptake and intracellular metabolism affecting ATP/ADP ratio and membrane depolarization leading to peptide secretion via Ca2+ channel activation[44]. While these mechanistic models do not directly measure vagal firing, they provide a plausible upstream endocrine stimulus that can influence vagal pathways and central appetite regulation when SCFAs are presented luminally in distal gut regions[16, 40].
Serotonin-mediated vagal signaling
A third route involves enterochromaffin serotonin signaling. A review of vagus–serotonin interactions states that SCFAs (mainly butyrate) in the gut lumen stimulate Tph1 expression in enterochromaffin cells, increasing serotonin production[12]. It further states that SCFAs modulate vagal activity and serotonin transporter (SERT) expression, strengthening the microbiota–gut–brain axis[12]. Importantly, it states that released 5-HT activates 5-HT3 receptors on afferent fibers of the vagus nerve and that signals are relayed through the nodose ganglion and processed in the nucleus tractus solitarius (NTS), spreading to other brain areas[12]. This framework provides an explicit mechanism whereby distal SCFA exposure could influence vagal signaling indirectly via mucosal mediator release rather than requiring direct access of SCFAs to vagal terminals[12].
Evidence for necessity of intact vagal pathways
In vivo intervention studies further support vagal dependence of butyrate effects. A mouse study reports that acute oral (but not intravenous) butyrate decreased food intake and decreased neuronal activity markers in the NTS and dorsal vagal complex, and that after subdiaphragmatic vagotomy, butyrate failed to reduce cumulative food intake, indicating that a gut–brain neural circuit is necessary for butyrate’s beneficial effects on satiety and brown adipose tissue activation[45]. In a distinct organ-system context, a rat myocardial ischemia/reperfusion study reports that oral butyrate may induce effects via gut–brain neural mechanisms that depend on afferent vagus nerve signaling, and that the protective effects were diminished by subdiaphragmatic vagotomy[46]. Although these models do not test colon-targeted formulations specifically, they reinforce a design hypothesis: achieving consistent gut-lumen exposure at the correct site can be a precondition for engaging vagus-dependent systemic physiology[45, 46].
Microbial metabolite interoception via small intestine
While the primary thesis here emphasizes colonic targeting, evidence also indicates small-intestinal SCFA exposure can modulate vagal activity in receptor-dependent ways. A study on microbial metabolites in the small intestinal lumen reports that perfusion of microbiome-dependent SCFAs into the small intestine produced slower onset and gradual increases in vagal afferent nerve activity[47]. It further reports that pre- and co-perfusion of an FFAR2 antagonist prevented the SCFA-induced increase in vagal afferent nerve activity[47], and that perfusion of microbial metabolites increased neuronal expression of cFos in the NTS to levels similar to sucrose perfusion[47]. A related report suggests that the latency could reflect differences in absorption rate or indirect signaling via non-neuronal mediators[48]. These findings imply that distal ileal delivery (not solely colonic delivery) may be sufficient for certain vagal outcomes, but that precise site selection still matters and may require formulations tuned to avoid gastric/proximal release while allowing distal small intestinal exposure[47, 48].
Translational and clinical evidence
Clinical and translational data in the supplied corpus spans three domains: (i) human pharmacokinetic studies demonstrating rapid systemic appearance of unprotected SCFAs, (ii) controlled or observational clinical studies using microencapsulated butyrate preparations in intestinal disease, and (iii) commercial claims that reflect real-world product strategies.
Human pharmacokinetics and formulation effects
A human supplementation study found that serum concentration profiles for orally ingested SCFAs peaked rapidly (peak circulating concentrations reached at 30–60 minutes post-ingestion and returned to baseline within 120 minutes)[5]. It also reports that an acid-resistant coated capsule caused a delayed and blunted blood concentration response compared with a non-acid resistant trial, consistent with delayed release altering systemic exposure kinetics[5]. These findings provide direct evidence that “enteric-like” protection can modulate timing and magnitude of systemic SCFA exposure, though the authors conclude that when systemic uptake is the desired outcome, no clear advantage is gained with acid-resistant capsules because delayed release lowers with similar tAUC[5]. Importantly, for the present thesis (distal neural sensing), lower and delayed systemic exposure may not be a disadvantage if it reflects improved distal luminal availability rather than reduced total delivery[5, 7].
A separate randomized crossover trial in healthy men comparing sodium butyrate, lysine butyrate, and tributyrin reports greater systemic butyrate exposure (AUC0-210 and ) and lower for sodium and lysine butyrate versus tributyrin[26]. The authors interpret reduced plasma appearance for tributyrin as likely due to enzymatic cleavage requirements that delay/reduce release from the prodrug[26]. Together, these studies reinforce that formulation strategy determines whether butyrate manifests as a rapid systemic pulse versus a delayed, potentially more distal exposure pattern[5, 26].
Microencapsulated sodium butyrate in ulcerative colitis and IBD
Evidence for microencapsulated sodium butyrate in inflammatory bowel disease includes both observational and randomized controlled contexts. In a prospective observational study in UC remission, patients receiving oral microencapsulated sodium butyrate (BLM) add-on therapy (two capsules/day for 12 months, 500 mg each) were compared against controls without therapy modification[38]. Therapeutic success at 12 months (Mayo partial score <=2 and fecal calprotectin <250 μg/g) was achieved in 15/18 (83.3%) in the BLM group versus 10/21 (47.6%) in controls[38], with higher subjective improvement (SIBDQ + VAS) at 6 and 12 months in the BLM group[38] and fecal calprotectin diminishing over time compared to stability in controls[38]. While this is observational, it supports feasibility of long-term microencapsulated dosing with clinically meaningful endpoints[38].
A separate pilot, double-blind, randomized, placebo-controlled study in IBD patients administered a microencapsulated sodium butyrate formulation (Butyrose® Lsc Microcaps) at 3 capsules/day (1800 mg/day) for 60 days and used a placebo group receiving starch capsules matched in color, flavor, and size[49]. The investigators report no significant differences in richness after treatment but describe modulation of microbiota composition and subjective improvement in quality of life by IBDQ in the butyrate group[49]. They additionally state that exogenous butyrate can modulate gut bacteria, stimulating growth of butyrogenic and SCFA genera that may produce more endogenous butyrate for restoration of intestinal homeostasis[49].
A clinical review of sodium butyrate and microencapsulated forms also summarizes that in IBS, six-week administration with MSB® significantly decreased abdominal pain and discomfort severity and improved quality of life compared with placebo (p < 0.0001)[7]. The same review notes that a 12-week adjunctive microencapsulated SB trial in newly diagnosed children/adolescents with IBD did not demonstrate effectiveness[7], underscoring heterogeneity of clinical responses and the need to match formulation, population, and endpoints[7, 20].
Diverticular disease and butyrate derivatives
A Spanish review reports a placebo-controlled diverticulosis study of 73 patients in which one group received 300 mg sodium butyrate, with a significant difference in diverticulitis episodes at 12 months for the group taking the butyric acid formulation; it also states that across these studies, different forms of butyric acid were well tolerated without adverse effects[24]. The same source describes a microencapsulated tributyrin oral formulation (BUTYCAPS) developed in 2016 and describes tributyrin as a triglyceride containing three butyrate molecules, acting as a source of butyric acid via lipase activity, with pharmacologic clinical studies indicating it is well tolerated[24]. It also states that microencapsulation can convert tributyrin into a granulate enabling once-daily administration and improved adherence[24].
Metabolic and brain-related translational signals
Evidence that oral butyrate can influence brain-related endpoints exists in animal and large-animal models, though not necessarily via enteric-coated delivery. In pigs, chronic sodium butyrate intake altered basal brain glucose metabolism in nucleus accumbens and hippocampus, increased hippocampal granular cell layer volume, and increased neurogenesis markers, while having limited effects on gut anatomy and function[2]. In the same study, the authors report no short-term effect on plasma gut hormones (PYY, GLP-1) and suggest butyrate may have been absorbed at the stomach level, preventing significant GLP-1 increase[2]. This interpretation again argues for distal-targeted formulations when the mechanistic intent involves L-cell endocrine signaling or vagal afferent engagement originating distally[2, 11].
Commercial and applied formulation context
Commercial materials reflect the same constraints identified in academic literature—stomach survival and colon targeting. A PubMed-indexed rat study description reports that highly dosed butyrate pellets (90%) were prepared with a pH-dependent coating (Eudragit L+S 1:1) chosen based on in vivo pH and transit time, designed for colonic delivery with ~6-hour resistance; the results did not show early absorption of butyrate, though probable cecal loss was noted due to cecal residence time and propitious pH for coating hydrolysis[50]. A clinical-facing product page for Natural Factors states “available in enteric-coated softgels for targeted delivery to the colon” and lists enteric softgel ingredients including pectin and sodium alginate, reflecting a commercially used enteric-protected strategy for oral butyrate delivery[51].
Web-based sources also describe microencapsulation as a response to butyrate’s sensory barrier. One article notes that the pungent odor and acrid taste of butyric acid make it unpalatable, framing this as a key challenge to supplement compliance, and describes a proprietary microencapsulation approach that “locks” molecules in a carrier to protect integrity during travel through the stomach and release at a desired intestinal point[52]. Another industry blog states that pure sodium butyrate has an intensely unpleasant odor and that microencapsulation/coating with a lipid or polymer matrix can physically trap volatile compounds, yielding a virtually odorless coated material[53]. While these sources are not controlled trials, they triangulate the practical necessity of odor masking and targeted release for consumer-facing use[53].
Conclusion
Across mechanistic, formulation, and clinical literatures, a coherent pattern emerges: the therapeutic potential of butyrate for gut–brain modulation depends on whether the molecule reaches anatomical sites capable of transducing neural signals—particularly distal intestine/colon regions with relevant receptors, enteroendocrine populations, and vagal afferent connectivity[3, 10, 11]. Multiple human and review sources indicate that free SCFA supplements can produce rapid systemic appearance likely due to passive stomach absorption, facilitated by SCFA weak-acid chemistry and nonionic diffusion across the gastric epithelium[5]. Concurrently, butyrate’s rancid odor/taste remains a consistent barrier to chronic adherence and motivates protected delivery systems[6, 7].
Enteric coatings and microencapsulation strategies offer integrated solutions: polymethacrylate pH-responsive coatings can prevent gastric release and shift dissolution toward ileal/colonic pH ranges, while combination coatings can mitigate pH variability that otherwise undermines reliability[8, 9, 35]. Microencapsulation—whether via lipid microbeads, polymer-coated microcapsules, protected beads, capsule-shell engineering, or polymeric prodrug micelles—can reduce release in gastric conditions, delay absorption, and physically isolate odorants to improve tolerability[6, 25, 37, 39]. Finally, gut–brain axis studies provide mechanistic plausibility that SCFAs can engage vagal and central pathways either directly through receptor-dependent afferent firing or indirectly through GLP-1/PYY and serotonin-mediated signaling[10–12].
The translational implication is that “enteric-targeted SCFAs” should be conceptualized as a formulation class rather than a single ingredient. The most defensible engineering goal, supported by the supplied sources, is to design delivery systems that remain intact under acidic gastric conditions, resist premature small-intestinal release under variable pH, and release butyrate in distal segments where receptor-mediated gut–brain signaling can occur, while providing robust odor/taste masking sufficient for long-term adherence[9, 25, 34].
